enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM

enGene Therapeutics Inc.

56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.
All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.
Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.
No other significant proposals; no change in board composition or auditor.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2026-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 2 – Appointment and Remuneration of Auditor For Withhold Broker Non-Votes 56,180,287 16,015 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

enGene Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Philip Astley-Sparke 47,112,414 306,821 8,777,067 Ronald H.W. Cooper 47,329,848 89,387 8,777,067 Dr. William Grossman 47,408,163 11,072 8,777,067 Michael Heffernan 47,408,163 11,072 8,777,067

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-265830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.